Cargando…

Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan

Seasonal influenza virus routinely causes epidemic infections throughout the world. Sporadic infections by H5N1, H5N6, and H7N9 viruses are also reported. To treat patients suffering from such viral infections, broadly reactive and highly sensitive influenza rapid diagnostic tests (IRDTs) are requir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai-Tagawa, Yuko, Yamayoshi, Seiya, Kawakami, Chiharu, Le, Mai Q., Uchida, Yuko, Saito, Takehiko, Nidom, Chairul A., Humaira, Ira, Toohey-Kurth, Kathy, Arafa, Abdel-Satar, Liu, Ming-Tsan, Shu, Yuelong, Kawaoka, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670212/ https://www.ncbi.nlm.nih.gov/pubmed/29101372 http://dx.doi.org/10.1038/s41598-017-14536-0

Ejemplares similares

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2019)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2021)

A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
por: Yasuhara, Atsuhiro, et al.
Publicado: (2022)

Influenza A (H5N1) Viruses from Pigs, Indonesia
por: Nidom, Chairul A., et al.
Publicado: (2010)

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies
por: Yasuhara, Atsuhiro, et al.
Publicado: (2017)

Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase
por: Takahashi, Tadanobu, et al.
Publicado: (2012)

Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans
por: Yamayoshi, Seiya, et al.
Publicado: (2018)

Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010
por: Nidom, Chairul A., et al.
Publicado: (2012)

Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses
por: Kiso, Maki, et al.
Publicado: (2010)

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan
por: Mitake, Hiromichi, et al.
Publicado: (2020)

Sensory and Compositional Properties Affecting the Likeability of Commercially Available Australian Honeys
por: Hunter, Maddison, et al.
Publicado: (2021)

Strain-Specific Contribution of Eukaryotic Elongation Factor 1 Gamma to the Translation of Influenza A Virus Proteins
por: Sammaibashi, Shuhei, et al.
Publicado: (2018)

Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity
por: Oishi, Kohei, et al.
Publicado: (2019)

Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
por: Kiso, Maki, et al.
Publicado: (2020)

The accuracy of reverse genetics systems for SARS‐CoV‐2: Circular polymerase extension reaction versus bacterial artificial chromosome
por: Furusawa, Yuri, et al.
Publicado: (2023)

The HA and NS Genes of Human H5N1 Influenza A Virus Contribute to High Virulence in Ferrets
por: Imai, Hirotaka, et al.
Publicado: (2010)

CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus
por: Yoshimi, Kazuto, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

G Protein Pathway Suppressor 1 Promotes Influenza Virus Polymerase Activity by Activating the NF-κB Signaling Pathway
por: Kuwahara, Tomoko, et al.
Publicado: (2019)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Complete and Incomplete Genome Packaging of Influenza A and B Viruses
por: Nakatsu, Sumiho, et al.
Publicado: (2016)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antibody-free digital influenza virus counting based on neuraminidase activity
por: Tabata, Kazuhito V., et al.
Publicado: (2019)

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
por: Kiso, Maki, et al.
Publicado: (2019)

Development of high-yield influenza A virus vaccine viruses
por: Ping, Jihui, et al.
Publicado: (2015)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021
por: Nidom, Reviany V., et al.
Publicado: (2021)

Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan
por: Soga, Takuma, et al.
Publicado: (2023)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses
por: Yasuhara, Atsuhiro, et al.
Publicado: (2018)

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018
por: Okuda, Moe, et al.
Publicado: (2019)

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China
por: Ma, Guangyu, et al.
Publicado: (2009)

Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
por: Maemura, Tadashi, et al.
Publicado: (2021)

A 265-Nanometer High-Power Deep-UV Light-Emitting Diode Rapidly Inactivates SARS-CoV-2 Aerosols
por: Ueki, Hiroshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f2cu3utic4j8i6ouc44nmli5sj